Working closing with the PharmaDiagnostics Synthetic Nanotechnology team, Sylviane’s appointment is the latest in a series of additions to further strengthen the PharmaDiagnostics R&D team. Sylviane will play a central role in driving the growth of PharmaDiagnostics’ assay product range, and via her extensive contacts in the market, in developing business globally. She will be closely involved in the product development strategy.
PharmaDiagnostics will benefit significantly from Sylviane’s considerable experience in pharmaceutical research and her knowledge of different screening technologies in drug discovery. Her move from a technology user to a provider gives PharmaDiagnostics valuable insight into market needs that will allow them to further develop their technology and product portfolio.
“Sylviane is a scientist of international renown, I am delighted to have her join our growing team. This is the latest mark of confidence from a leading industry figure, and follows on from the appointment of Ulf Jönsson, the former CEO of Biacore, as an independent director,” said David Ricketts, CEO, PharmaDiagnostics. “This clearly demonstrates the market potential of our SoPRano technology to revolutionize label-free screening. We have removed the need for expensive dedicated instruments and therefore can significantly expand the application of label-free screening in drug discovery.”
“Having worked for a global pharmaceutical corporation, I was keen to join an innovative, growing company with an exciting technology with significant commercial potential,” said Dr Sylviane Boucharens. “PharmaDiagnostics’ technical capabilities in label-free screening, together with its ambitious growth plans promise a true revolution in the screening market and I am looking forward to contributing to its success.”
Sylviane worked at Merck from 2000 to 2011 (Legacy Schering-Plough Research Institute & Organon Laboratories Ltd.) as the head of global compound repository and in vitro screening. Sylviane attained her PhD from the University of Grenoble, France, followed by post-doctoral positions at the INSERM U366 Laboratory, Grenoble, France and University of Manchester, UK under the Wellcome Trust International Fellowship. She started her career in the pharmaceutical industry in 1995 when she joined the Immunology Department in the Laboratoires Fournier (Dijon, France).